These findings have provided valuable insights into the management of T2D and informed clinical practice guidelines and regulatory decisions.GLP-1 receptor agonists have emerged as an important therapeutic option for individuals with T2D, particularly those at high risk of CVD
Often called the Triple G peptide, this investigational medication from Eli Lilly is showing results in clinical trials that we once thought were impossible without a scalpel
Medication timing and absorption issues While less common as a primary stall cause, inconsistent medication timing can affect blood levels and efficacy
Alterations in gut microbiota composition and increased intestinal permeability (leaky gut) may exacerbate systemic and neurogenic inflammation
The GLP-1R is widely expressed in multiple regions of the rodent and human brain, and activation of GLP-1R + neurons in the hypothalamus and brainstem reduces food intake and promotes weight loss
While this has not been conclusively demonstrated in humans, it remains a concern, especially in those with a personal or family history of thyroid cancer